Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 149-152

  Galluzzo, Mariangela ^a   Pintor, Anita ^a   Pèzzola, Antonella ^a   Grieco, Rosa ^a   Borsini, Franco ^b   Popoli, Patrizia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

Adenosine A2A receptor antagonist; Glutamate; Microdialysis; ST1575

Indexed keywords

2 BUTYL 9 METHYL 8 (2H 1,2,3 TRIAZOL 2 YL) 9 H PURIN 6 YLAMINE; ADENOSINE A2A RECEPTOR ANTAGONIST; GLUTAMIC ACID; QUINOLINIC ACID; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG DOSE COMPARISON; EXCITOTOXICITY; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENINE; ANIMALS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; QUINOLINIC ACID; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; TRIAZOLES;

EID: 37549043239     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.057     Document Type: Article

References (24)

1. Blum D., Galas M.C., Pintor A., Brouillet E., Ledent C., Muller C.E., Bantubungi K., Galluzzo M., Gall D., Cuvelier L., Rolland A.-S., Popoli P., and Schiffmann S.N. A dual role of adenosine A2A receptors in the 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23 (2003) 5361-5369
2. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 RC143 (2001) 1-6
3. 2A receptor heteromers. J. Neurosci. 26 (2006) 2080-2087
4. 2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur. J. Pharmacol. 464 (2003) 33-38
5. Fuxe K., Stromberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S.O., Franco R., Agnati L.F., and Ferré S. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv. Neurol. 86 (2001) 345-353
6. 2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80 (2002) 262-270
7. Karcz-Kubicha M., Antoniou K., Terasmaa A., Quarta D., Solinas M., Justinova Z., Pèzzola A., Reggio R., Muller C.E., Fuxe K., Goldberg S.R., Popoli P., and Ferré S. Involvement of adenosine A(1) and A(2A) receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28 (2003) 1281-1291
8. Marchi M., Raiteri L., Risso F., Vallarino A., Bonfanti A., Monopoli A., Ongini E., and Raiteri M. Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br. J. Pharmacol. 136 (2002) 434-440
9. 2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J. Med. Chem. 48 (2005) 6887-6896
10. 2A antagonists: potential preventive and palliative treatment for Parkinson's disease. Exp. Neurol. 184 (2003) 20-23
11. 2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox. Res. 3 (2001) 545-566
12. 2A adenosine receptors: an apparent paradox. Drug Dev. Res. 45 (1998) 387-392
13. 2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705 (1995) 79-84
14. 2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine (DA) rat model of Parkinson's disease. Synapse 61 (2007) 606-614
15. 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate up take inhibitors. J. Neurochem. 89 (2004) 152-156
16. 2a receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287 (1995) 215-217
17. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22 (2002) 1967-1975
18. 2A receptors. Neurology 61 11 Suppl 6 (2003) S69-S77
19. 2Areceptor antagonism and neuroprotection: mechanisms, lights, and shadows. Crit. Rev. Neurobiol. 16 (2004) 99-106
20. 2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J. Neurochem. 88 (2004) 1151-1158
21. 2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets. Eur. J. Pharmacol. 546 (2006) 82-87
22. Schwarzschild M.A., Chen J.F., and Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 58 (2002) 1154-1160
23. 2A adenosine receptor antagonist. Int. J. Neuropsychopharmacol. 9 (2006) 575-584
24. 2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. J. Neurosci. Res. 77 (2004) 100-107